Skip to main content
. 2021 Sep 7;20:15347354211035450. doi: 10.1177/15347354211035450

Figure 5.

Figure 5.

Caspase 3 activity. (a) Caspase 3 activity in HCT116 and MCF7 treated with thymoquinone (TQ, 50 µM). (b) Caspase 3 activity in HCT116 and MCF7 treated with costunolide (COS, 30 µM). Error bars represent mean ± SD. *P < .05, **P < .01, and ***P < .001 versus control. xxxP < .001 versus HCT116 + COS or MCF7 + COS. Control refers to proliferative-untreated HCT116 or -untreated MCF7. HCT116 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. MCF7 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. HCT116 + COS refers to HCT116 treated with 30 µM COS for 24 hours. MCF7 + COS refers to HCT116 treated with 30 µM COS for 24 hours. Control refers to proliferative-untreated HCT116 or -untreated MCF7. HCT116 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. MCF7 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. Dox5 refers to Sen-HCT116 or Sen-MCF7 with 100 nM Dox for 5 days. HCT116 + Dox5 + TQ refers to Sen-HCT116 with 100 nM Dox for 5 days, then treated with 50 µM TQ for 24 hours. MCF7 + Dox5 + TQ refers to Sen-MCF7 with 100 nM Dox for 5 days then treated with 50 µM TQ for 24 hour. TQ, thymoquinone; COS, costunolide. All assays were done in triplicate at least.